LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under reviewCOMP360 phase II study in anorexia
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which.